The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma (rGBM).
 
Stephen Bagley
Consulting or Advisory Role - KIYATEC; Modifi Bio; SERVIER; Telix Pharmaceuticals; Third Rock Ventures
Research Funding - C2i genomics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kite, a Gilead company; Kite, a Gilead company; Lilly (Inst); Novocure (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of intellectual property of the University of Pennsylvania licensed to Novartis: Combination Therapies of EGFRvIII Chimeric Antigen Receptors and PD-1 Inhibitors, US. Patent No. 62/809,245.
Travel, Accommodations, Expenses - Northwest Biotherapeutics
 
Zev Binder
Consulting or Advisory Role - Bristol-Myers Squibb (I); Foundation Medicine (I); Guardant Health (I); Merus (I); MOMA Therapeutics (I); Synovation (I)
Research Funding - Kite, a Gilead company
Patents, Royalties, Other Intellectual Property - Patents relating to CAR T cell therapy for glioblastoma
 
Joseph Fraietta
Consulting or Advisory Role - Cartography Bio; Shennon Biotechnologies
 
Arati Desai
No Relationships to Disclose
 
Ali Nabavizadeh
No Relationships to Disclose
 
Amy Marshall
No Relationships to Disclose
 
Rachel Leskowitz
No Relationships to Disclose
 
Vanessa Gonzalez
No Relationships to Disclose
 
Whitney Gladney
Employment - Kite, a Gilead Company
 
David Barrett
Employment - Kite, a Gilead Company
 
Dana Silverbush
No Relationships to Disclose
 
Nelson Freeburg
No Relationships to Disclose
 
Daniel Chafamo
No Relationships to Disclose
 
Gayathri Konanur
No Relationships to Disclose
 
MacLean Nasrallah
No Relationships to Disclose
 
Wei-Ting Hwang
Employment - Johnson & Johnson innovative medicine (I)
Stock and Other Ownership Interests - Johnson & Johnson innovative medicine (I)
Research Funding - Novartis
 
Donald Siegel
Stock and Other Ownership Interests - Verismo Therapeutics; Vetigenics
Patents, Royalties, Other Intellectual Property - IP licensing to Chimeric Therapeutics
 
Carl June
Leadership - AC Immune
Stock and Other Ownership Interests - BlueWhale Bio; Capstan Therapeutics; Dispatch Biotherapeutics
Consulting or Advisory Role - BlueSphereBio; Cabaletta Bio; Carisma Therapeutics; Cartography; Cellares; Cellcarta; Celldex; Danaher; Decheng Capital; ImmuneSensor Therapeutics; Kite, a Gilead Company; Poseida Therapeutics; Verismo Therapeutics; Viracta Therapeutics; Vittoria Biotherapeutics; WIRB-Copernicus Group
Patents, Royalties, Other Intellectual Property - Kite, a Gilead Company; Novartis
 
Elizabeth Hexner
No Relationships to Disclose
 
Donald O'Rourke
Consulting or Advisory Role - Celldex; Century Therapeutics; Chimeric Therapeutics; Prescient Therapeutics
Research Funding - Celldex (Inst); Kite, a Gilead Company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - inventor of IP (US patent numbers 7,625,558 and 6,417,168 and related families) and has received royalties related to targeted ErbB therapy in solid cancers